• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

泪液渗透压和眼表参数作为眼部移植物抗宿主病的诊断标志物

Tear Osmolarity and Ocular Surface Parameters as Diagnostic Markers of Ocular Graft-Versus-Host Disease.

作者信息

Na Kyung-Sun, Yoo Young-Sik, Hwang Kyu-Yeon, Mok Jee-Won, Joo Choun-Ki

机构信息

Department of Ophthalmology and Visual Science, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea; Laboratory of Visual Science, College of Medicine, The Catholic University of Korea, Seoul, South Korea.

Laboratory of Visual Science, College of Medicine, The Catholic University of Korea, Seoul, South Korea.

出版信息

Am J Ophthalmol. 2015 Jul;160(1):143-9.e1. doi: 10.1016/j.ajo.2015.04.002. Epub 2015 Apr 11.

DOI:10.1016/j.ajo.2015.04.002
PMID:25870935
Abstract

PURPOSE

To evaluate the diagnostic value of tear osmolarity and several ocular surface parameters in screening for ocular surface alterations in ocular graft-vs-host disease (GVHD) patients.

DESIGN

Case-control study.

METHODS

Sixty-three patients with ocular GVHD and 74 healthy participants were screened for ocular surface changes using the Ocular Surface Disease Index (OSDI), tear osmolarity, Schirmer test, tear break-up time (TBUT), and fluorescein corneal staining. The severity of ocular GVHD was diagnosed according to the National Institutes of Health (NIH) grading system. The diagnostic sensitivity and specificity and cutoff values were determined for each ocular parameter using a receiver operating characteristic (ROC) curve and area under the curve (AUC) analysis. Significance was defined at P < .05.

RESULTS

The tear osmolarity, corneal staining score, and OSDI score gradually increased as the severity of ocular GVHD increased, and Schirmer value gradually decreased as the GVHD grade increased in severity. The Schirmer test showed greatest diagnostic sensitivity and specificity for ocular GVHD (92.1% sensitivity, 85.7% specificity, cutoff = 9 mm), followed by the TBUT (87.3% sensitivity, 75.0% specificity, cutoff = 6 s), tear osmolarity (98.4% sensitivity, 60.7% specificity, cutoff = 311 mOsm/L), corneal staining score (66.7% sensitivity, 82.1% specificity, cutoff = 2), and OSDI score (77.8% sensitivity, 66.1% specificity, cutoff = 20.8).

CONCLUSIONS

Multiple diagnostic modalities should be used to detect ocular surface changes in GVHD patients. The severity of ocular GVHD can be effectively monitored using tear osmolarity; however, additional studies are required.

摘要

目的

评估泪液渗透压及多项眼表参数在筛查眼部移植物抗宿主病(GVHD)患者眼表改变中的诊断价值。

设计

病例对照研究。

方法

采用眼表疾病指数(OSDI)、泪液渗透压、泪液分泌试验、泪膜破裂时间(TBUT)及荧光素角膜染色对63例眼部GVHD患者和74名健康参与者进行眼表变化筛查。根据美国国立卫生研究院(NIH)分级系统诊断眼部GVHD的严重程度。使用受试者工作特征(ROC)曲线和曲线下面积(AUC)分析确定每个眼部参数的诊断敏感性、特异性及临界值。P <.05为有统计学意义。

结果

随着眼部GVHD严重程度增加,泪液渗透压、角膜染色评分及OSDI评分逐渐升高,泪液分泌试验值随GVHD严重程度增加而逐渐降低。泪液分泌试验对眼部GVHD显示出最高的诊断敏感性和特异性(敏感性92.1%,特异性85.7%,临界值 = 9 mm),其次是TBUT(敏感性87.3%,特异性75.0%,临界值 = 6 s)、泪液渗透压(敏感性98.4%,特异性60.7%,临界值 = 311 mOsm/L)、角膜染色评分(敏感性66.7%,特异性82.1%,临界值 = 2)及OSDI评分(敏感性77.8%,特异性66.1%,临界值 = 20.8)。

结论

应采用多种诊断方法检测GVHD患者的眼表变化。泪液渗透压可有效监测眼部GVHD的严重程度;然而,仍需进一步研究。

相似文献

1
Tear Osmolarity and Ocular Surface Parameters as Diagnostic Markers of Ocular Graft-Versus-Host Disease.泪液渗透压和眼表参数作为眼部移植物抗宿主病的诊断标志物
Am J Ophthalmol. 2015 Jul;160(1):143-9.e1. doi: 10.1016/j.ajo.2015.04.002. Epub 2015 Apr 11.
2
Correlation Between Tear Film Osmolarity and the Disease Score of the International Chronic Ocular Graft-Versus-Host-Disease Consensus Group in Hematopoietic Stem Cell Transplantation Patients.造血干细胞移植患者泪膜渗透压与国际慢性眼部移植物抗宿主病共识组疾病评分的相关性
Cornea. 2015 Aug;34(8):911-6. doi: 10.1097/ICO.0000000000000494.
3
Tear osmolarity in ocular graft-versus-host disease.眼移植物抗宿主病中的泪液渗透压
Cornea. 2014 Dec;33(12):1252-6. doi: 10.1097/ICO.0000000000000283.
4
Comparison of ocular surface disease index and tear osmolarity as markers of ocular surface dysfunction in video terminal display workers.视频终端显示作业人员眼表功能障碍的眼表疾病指数和泪液渗透压标志物比较。
Am J Ophthalmol. 2014 Jul;158(1):41-48.e2. doi: 10.1016/j.ajo.2014.03.007. Epub 2014 Mar 13.
5
Performance of tear osmolarity compared to previous diagnostic tests for dry eye diseases.泪液渗透压与其他干眼病诊断测试的性能比较。
Curr Eye Res. 2010 Jul;35(7):553-64. doi: 10.3109/02713683.2010.484557.
6
Correlation between tear film osmolarity, dry eye disease, and rheumatoid arthritis.泪膜渗透压、干眼症与类风湿关节炎之间的相关性。
Cornea. 2014 Dec;33(12):1257-61. doi: 10.1097/ICO.0000000000000257.
7
Correlation of Tear Film Osmolarity and 2 Different MMP-9 Tests With Common Dry Eye Tests in a Cohort of Non-Dry Eye Patients.在一组非干眼患者中,泪膜渗透压及两种不同基质金属蛋白酶-9(MMP-9)检测与常见干眼检测的相关性
Cornea. 2015 Jul;34(7):739-44. doi: 10.1097/ICO.0000000000000449.
8
Tear film osmolarity in ocular mucous membrane pemphigoid.眼黏膜类天疱疮中的泪膜渗透压
Cornea. 2014 Jul;33(7):668-72. doi: 10.1097/ICO.0000000000000148.
9
Correlation of Dry Eye Workshop Dry Eye Severity Grading System With Tear Meniscus Measurement by Optical Coherence Tomography and Tear Osmolarity.干眼研讨会干眼严重程度分级系统与光学相干断层扫描测量泪河高度及泪液渗透压的相关性
Eye Contact Lens. 2016 May;42(3):153-7. doi: 10.1097/ICL.0000000000000168.
10
Assessment of dry eye in a GVHD murine model: Approximation through tear osmolarity measurement.移植物抗宿主病小鼠模型中干眼症的评估:通过泪液渗透压测量进行近似评估。
Exp Eye Res. 2017 Jan;154:64-69. doi: 10.1016/j.exer.2016.11.004. Epub 2016 Nov 3.

引用本文的文献

1
Tear fluid derived extracellular vesicles for new biomarker discovery.用于发现新型生物标志物的泪液来源细胞外囊泡
Ocul Surf. 2025 Jul;37:314-322. doi: 10.1016/j.jtos.2025.05.001. Epub 2025 May 12.
2
A brief account on ocular graft versus host disease.眼移植物抗宿主病简述。
Indian J Ophthalmol. 2023 Apr;71(4):1115-1122. doi: 10.4103/IJO.IJO_2839_22.
3
Challenges and concepts in the diagnosis and management of ocular graft-versus-host disease.眼部移植物抗宿主病诊断与管理中的挑战与概念
Front Med (Lausanne). 2023 Feb 16;10:1133381. doi: 10.3389/fmed.2023.1133381. eCollection 2023.
4
Ocular graft-versus-host disease (oGVHD): From A to Z.眼移植物抗宿主病(oGVHD):从 A 到 Z。
Surv Ophthalmol. 2023 Jul-Aug;68(4):697-712. doi: 10.1016/j.survophthal.2023.02.006. Epub 2023 Mar 2.
5
Ocular surface disease index questionnaire as a sensitive test for primary screening of chronic ocular graft-versus-host disease.眼表疾病指数问卷作为慢性眼部移植物抗宿主病初步筛查的敏感检测方法。
Ann Transl Med. 2022 Aug;10(16):855. doi: 10.21037/atm-21-6946.
6
Outcomes and complications of cataract surgery in patients with chronic ocular graft-versus-host-disease-a multicenter, retrospective analysis.慢性眼移植物抗宿主病患者白内障手术的结果和并发症:一项多中心回顾性分析。
Graefes Arch Clin Exp Ophthalmol. 2022 Aug;260(8):2613-2622. doi: 10.1007/s00417-022-05613-w. Epub 2022 Mar 7.
7
Update on ocular graft-versus-host disease.眼移植物抗宿主病的最新进展。
Indian J Ophthalmol. 2021 May;69(5):1038-1050. doi: 10.4103/ijo.IJO_2016_20.
8
Ocular surface system alterations in ocular graft-versus-host disease: all the pieces of the complex puzzle.眼部移植物抗宿主病中的眼表系统改变:复杂谜题的所有碎片。
Graefes Arch Clin Exp Ophthalmol. 2019 Jul;257(7):1341-1351. doi: 10.1007/s00417-019-04301-6. Epub 2019 Apr 3.
9
Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.造血细胞移植后眼移植物抗宿主病:来自 CIBMTR 晚期效应和生活质量工作组以及 EBMT 移植并发症工作组的专家综述。
Bone Marrow Transplant. 2019 May;54(5):662-673. doi: 10.1038/s41409-018-0340-0. Epub 2018 Dec 7.
10
Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.造血细胞移植后眼移植物抗宿主病:来自国际血液和骨髓移植研究中心晚期效应和生活质量工作组以及欧洲血液和骨髓移植学会移植并发症工作组的专家综述。
Biol Blood Marrow Transplant. 2019 Feb;25(2):e46-e54. doi: 10.1016/j.bbmt.2018.11.021. Epub 2018 Nov 24.